Jacqueline T. Bork
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jacqueline T. Bork has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
Emily L. Heil
University of Maryland School of Pharmacy
3 shared publicationsAnthony Amoroso
University of Maryland School of Medicine
2 shared publications- Danica Palacio
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
2 shared publications - David James Riedel
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
2 shared publications - Djordje Atanackovic
Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA
2 shared publications - Jean A. Yared
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
2 shared publications
Latest Publications
- Open Access
Changes in C-Reactive Protein Forecast Infection Risk Following Treatment with Chimeric Antigen Receptor T Cells
Background. Immunosuppressive conditioning regimens for chimeric antigen receptor-modified T cell immunotherapy (CARTx) and subsequent T cell dysfunction increase risk for infection. However, it is difficult to discern infection from CRS in the early (up to Day 30) and late (Days 31–180) periods after CARTx due to overlapping signs and symptoms. Methods. We analyzed infectious complications and predictors of infection during the early and late periods after CARTx in 213 adult patients with malignancies over a 5-year period. Results. Overall, 75 patients (35%) had at least one infection, mostly within the first 30 days after CARTx. Infections occurring early after CARTx were mostly bacterial, whereas viral infections predominated after Day 30. In multivariate analyses, a high baseline CRP (≥5 mg/dL) was significantly associated with increased risk of infection in the early period after CARTx, and a Day-5-to-baseline-CRP ratio of <1.5 was significantly associated with a higher risk of infection through all 180 days after CARTx and during the late period after CARTx. Conclusions. Infections in adult patients are common up to 180 days after receiving CARTx. High baseline CRP without significant temporal changes may predict risk of infection. Tracking CRP trends may be a useful clinical tool for discerning causes of fever and guiding antibiotic stewardship in this population at high risk for infections.
Open AccessChanges in C-Reactive Protein Forecast Infection Risk Following Treatment with Chimeric Antigen Receptor T Cells
Background. Immunosuppressive conditioning regimens for chimeric antigen receptor-modified T cell immunotherapy (CARTx) and subsequent T cell dysfunction increase risk for infection. However, it is difficult to discern infection from CRS in the early (up to Day 30) and late (Days 31–180) periods after CARTx due to overlapping signs and symptoms. Methods. We analyzed infectious complications and predictors of infection during the early and late periods after CARTx in 213 adult patients with malignancies over a 5-year period. Results. Overall, 75 patients (35%) had at least one infection, mostly within the first 30 days after CARTx. Infections occurring early after CARTx were mostly bacterial, whereas viral infections predominated after Day 30. In multivariate analyses, a high baseline CRP (≥5 mg/dL) was significantly associated with increased risk of infection in the early period after CARTx, and a Day-5-to-baseline-CRP ratio of <1.5 was significantly associated with a higher risk of infection through all 180 days after CARTx and during the late period after CARTx. Conclusions. Infections in adult patients are common up to 180 days after receiving CARTx. High baseline CRP without significant temporal changes may predict risk of infection. Tracking CRP trends may be a useful clinical tool for discerning causes of fever and guiding antibiotic stewardship in this population at high risk for infections.
- Open Access
- 18 November 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (22) , 5880-5884
Coordinated antiviral immune response in a patient with myeloma and systemic adenovirus infection post-BCMA CAR T cells
- 18 November 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (22) , 5880-5884
Open AccessCoordinated antiviral immune response in a patient with myeloma and systemic adenovirus infection post-BCMA CAR T cells
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
2717. Beware the bacteria: risk of bacterial infections persists more than 60 days post CAR-T
Immunosuppressive conditioning regimens for chimeric antigen receptor-modified T cells (CAR-T) and subsequent T cell dysfunction increase risk for infection. Prior studies of infection risk after CAR-T have found bacterial infections are most common in the first month, and viral infections are more frequently seen after 30 days. We evaluated longer-term infection outcomes, up to 180 days post CAR-T infusion. We performed a retrospective chart review of 144 patients who received CAR-T infusion at our institution between March 2018 and March 2022. We collected data on demographics, type and timing of infections, onset and treatment of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) or Cytokine Release Syndrome (CRS), and mortality up to 180 days after CAR-T infusion. We determined if ICANS, CRS, or treatment for either was associated with infections using Chi-square test. The mean age of patients in our cohort was 59 years. Most patients were male (65%), White (66%), and had not received a prior stem cell transplant (78%). Fifty-one (35%) patients had at least one infection during the study period (29% bacterial, 13% viral, 2% fungal). Mortality was 23% at 180 days. Most infections occurred within 60 days post CAR-T (Figure 1). Infections occurring between days 61 and 180 were mostly bacterial. In addition, ICANS ≥grade 3 and CRS ≥grade 2 occurred in 22 (15%) and 54 (38%) patients, respectively; both were significantly associated with bacterial infection (p< 0.05). Infections 180 days after CAR-T. *includes bacteremia, pneumonia, and skin and soft tissue infections. This cohort analyzed long-term infection outcomes post CAR-T. Most infections occurred early after CAR-T, within 60 days, and ICANS and CRS were associated with bacterial infection. We found that infections still persisted late after CAR-T, between Days 61 and 180, and were predominately bacterial, rather than viral or fungal. The low rates of fungal infection throughout the study period may be due to our institution’s fungal prophylaxis protocol. Future analyses will elucidate risk factors for infections in the late CAR-T period. David J. Riedel, MD, MPH , Gilead: Advisor/Consultant
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access2717. Beware the bacteria: risk of bacterial infections persists more than 60 days post CAR-T
Immunosuppressive conditioning regimens for chimeric antigen receptor-modified T cells (CAR-T) and subsequent T cell dysfunction increase risk for infection. Prior studies of infection risk after CAR-T have found bacterial infections are most common in the first month, and viral infections are more frequently seen after 30 days. We evaluated longer-term infection outcomes, up to 180 days post CAR-T infusion. We performed a retrospective chart review of 144 patients who received CAR-T infusion at our institution between March 2018 and March 2022. We collected data on demographics, type and timing of infections, onset and treatment of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) or Cytokine Release Syndrome (CRS), and mortality up to 180 days after CAR-T infusion. We determined if ICANS, CRS, or treatment for either was associated with infections using Chi-square test. The mean age of patients in our cohort was 59 years. Most patients were male (65%), White (66%), and had not received a prior stem cell transplant (78%). Fifty-one (35%) patients had at least one infection during the study period (29% bacterial, 13% viral, 2% fungal). Mortality was 23% at 180 days. Most infections occurred within 60 days post CAR-T (Figure 1). Infections occurring between days 61 and 180 were mostly bacterial. In addition, ICANS ≥grade 3 and CRS ≥grade 2 occurred in 22 (15%) and 54 (38%) patients, respectively; both were significantly associated with bacterial infection (p< 0.05). Infections 180 days after CAR-T. *includes bacteremia, pneumonia, and skin and soft tissue infections. This cohort analyzed long-term infection outcomes post CAR-T. Most infections occurred early after CAR-T, within 60 days, and ICANS and CRS were associated with bacterial infection. We found that infections still persisted late after CAR-T, between Days 61 and 180, and were predominately bacterial, rather than viral or fungal. The low rates of fungal infection throughout the study period may be due to our institution’s fungal prophylaxis protocol. Future analyses will elucidate risk factors for infections in the late CAR-T period. David J. Riedel, MD, MPH , Gilead: Advisor/Consultant
- Open Access
- 7 August 2023
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 3 (1) , e137
Developing a diagnosis calculator to estimate the probability of bacterial pneumonia
Misdiagnosis of bacterial pneumonia increases risk of exposure to inappropriate antibiotics and adverse events. We developed a diagnosis calculator (https://calculator.testingwisely.com) to inform clinical diagnosis of community-acquired bacterial pneumonia using objective indicators, including incidence of disease, risk factors, and sensitivity and specificity of diagnostic tests, that were identified through literature review.
- 7 August 2023
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 3 (1) , e137
Open AccessDeveloping a diagnosis calculator to estimate the probability of bacterial pneumonia
Misdiagnosis of bacterial pneumonia increases risk of exposure to inappropriate antibiotics and adverse events. We developed a diagnosis calculator (https://calculator.testingwisely.com) to inform clinical diagnosis of community-acquired bacterial pneumonia using objective indicators, including incidence of disease, risk factors, and sensitivity and specificity of diagnostic tests, that were identified through literature review.
- Open Access
- 1 August 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (9) , ofad412
Improving the Efficiency of Antimicrobial Stewardship Action in Acute Care Facilities
Inpatient antimicrobial stewardship (AS) programs are quality improvement programs tasked with improving antibiotic practices by augmenting frontline providers’ antibiotic prescription. Prospective audit and feedback (PAF) and preauthorization (PRA) are essential activities in the hospital that can be resource intensive for AS teams. Improving efficiency in AS activities is needed when there are limited resources or when programs are looking to expand tasks beyond PAF and PRA, such as broad education or guideline development. Guidance on the creation and maintenance of alerts for the purpose of PAF reviews, modifications of antibiotic restrictions for PRA polices, and overall initiative prioritization strategies are reviewed. In addition, daily prioritization tools, such as the tiered approach, scoring systems, and regression modeling, are available for stewards to prioritize their daily workflow. Using these tools and guidance, AS programs can be productive and impactful in the face of resource limitation or competing priorities in the hospital.
- 1 August 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (9) , ofad412
Open AccessImproving the Efficiency of Antimicrobial Stewardship Action in Acute Care Facilities
Inpatient antimicrobial stewardship (AS) programs are quality improvement programs tasked with improving antibiotic practices by augmenting frontline providers’ antibiotic prescription. Prospective audit and feedback (PAF) and preauthorization (PRA) are essential activities in the hospital that can be resource intensive for AS teams. Improving efficiency in AS activities is needed when there are limited resources or when programs are looking to expand tasks beyond PAF and PRA, such as broad education or guideline development. Guidance on the creation and maintenance of alerts for the purpose of PAF reviews, modifications of antibiotic restrictions for PRA polices, and overall initiative prioritization strategies are reviewed. In addition, daily prioritization tools, such as the tiered approach, scoring systems, and regression modeling, are available for stewards to prioritize their daily workflow. Using these tools and guidance, AS programs can be productive and impactful in the face of resource limitation or competing priorities in the hospital.
- 26 July 2023
- Published by Springer Nature in Current Fungal Infection Reports
- Vol. 17 (3) , 188-194
A Scoping Review of the Changing Epidemiology and Risk Factors of Endogenous Candida Ocular Infections
- 26 July 2023
- Published by Springer Nature in Current Fungal Infection Reports
- Vol. 17 (3) , 188-194
A Scoping Review of the Changing Epidemiology and Risk Factors of Endogenous Candida Ocular Infections
- 4 July 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 77 (9) , 1234-1237
Infectious Diseases Consultation Associated With Reduced Mortality in Gram-Negative Bacteremia
Gram-negative bacteremia (GN-BSI) can cause significant morbidity and mortality, but the benefit of infectious diseases consultation (IDC) is not well defined. A 24-site observational cohort study of unique hospitalized patients with 4861 GN-BSI episodes demonstrated a 40% decreased risk of 30-day mortality in patients with IDC compared to those without IDC.
- 4 July 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 77 (9) , 1234-1237
Infectious Diseases Consultation Associated With Reduced Mortality in Gram-Negative Bacteremia
Gram-negative bacteremia (GN-BSI) can cause significant morbidity and mortality, but the benefit of infectious diseases consultation (IDC) is not well defined. A 24-site observational cohort study of unique hospitalized patients with 4861 GN-BSI episodes demonstrated a 40% decreased risk of 30-day mortality in patients with IDC compared to those without IDC.
- 1 March 2021
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 99 (3) , 115261
Multicenter retrospective cohort study of the clinical significance of Staphylococcus lugdunensis isolated from a single blood culture set
- 1 March 2021
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 99 (3) , 115261
Multicenter retrospective cohort study of the clinical significance of Staphylococcus lugdunensis isolated from a single blood culture set
- Open Access
- 10 December 2020
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 42 (9) , 1115-1117
Change in hospital antibiotic use and acquisition of multidrug-resistant gram-negative organisms after the onset of coronavirus disease 2019
Interrupted time series segmented regression was conducted to trend antibiotic use and multidrug-resistant gram-negative (MDRGN) acquisition relative to COVID-19 in an academic hospital. Total antibiotic use and antibiotic use related to pneumonia was higher in the period after the onset of COVID-19 compared to the similar calendar period in 2019. Furthermore, MDRGN acquisition increased 3% for every increase in positive COVID-19 tests per week.
- 10 December 2020
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 42 (9) , 1115-1117
Open AccessChange in hospital antibiotic use and acquisition of multidrug-resistant gram-negative organisms after the onset of coronavirus disease 2019
Interrupted time series segmented regression was conducted to trend antibiotic use and multidrug-resistant gram-negative (MDRGN) acquisition relative to COVID-19 in an academic hospital. Total antibiotic use and antibiotic use related to pneumonia was higher in the period after the onset of COVID-19 compared to the similar calendar period in 2019. Furthermore, MDRGN acquisition increased 3% for every increase in positive COVID-19 tests per week.
- Open Access
- 29 July 2020
- Published by Springer Nature in Cureus
- Vol. 12 (7) , e9463
Agranulocytosis Following COVID-19 Recovery
Clinicians have continued to report on the clinical behavior and characteristics of patients with coronavirus disease 2019 (COVID-19) as our knowledge of the virus continues to mature. Herein, we report the case of a 39-year-old male with multiple comorbidities who became critically ill with COVID-19 infection, requiring mechanical ventilation and vasopressors, and then developed agranulocytosis following clinical improvement and resolution of symptoms of COVID infection. The period of agranulocytosis coincided with the development of thrombocytosis, and following resolution of agranulocytosis, the platelet count also normalized, suggesting a possible related mechanism. Interestingly, the patient was treated with TBO-filgrastim 480 mcg daily with a rapid reconstitution of neutrophils. While the mechanism of agranulocytosis remains unknown, we report, to our knowledge, the first known case of agranulocytosis following COVID-19 infection and its successful treatment with granulocyte colony-stimulating factor.
- 29 July 2020
- Published by Springer Nature in Cureus
- Vol. 12 (7) , e9463
Open AccessAgranulocytosis Following COVID-19 Recovery
Clinicians have continued to report on the clinical behavior and characteristics of patients with coronavirus disease 2019 (COVID-19) as our knowledge of the virus continues to mature. Herein, we report the case of a 39-year-old male with multiple comorbidities who became critically ill with COVID-19 infection, requiring mechanical ventilation and vasopressors, and then developed agranulocytosis following clinical improvement and resolution of symptoms of COVID infection. The period of agranulocytosis coincided with the development of thrombocytosis, and following resolution of agranulocytosis, the platelet count also normalized, suggesting a possible related mechanism. Interestingly, the patient was treated with TBO-filgrastim 480 mcg daily with a rapid reconstitution of neutrophils. While the mechanism of agranulocytosis remains unknown, we report, to our knowledge, the first known case of agranulocytosis following COVID-19 infection and its successful treatment with granulocyte colony-stimulating factor.